Dynavax, Bavarian Nordic Ink Distribution Pact For Hepatitis B Vaccine In Germany

  • Dynavax Technologies Corporation DVAX has entered into a commercialization agreement with Bavarian Nordic for the marketing and distribution of HEPLISAV B, the Hepatitis B vaccine in Germany, with an expected launch in the fourth quarter of 2021.
  • Financial terms were not disclosed.
  • In February, the European Commission granted marketing authorization for HEPLISAV B.
  • The vaccine combines hepatitis B surface antigen with Dynavax's proprietary Toll-like Receptor (TLR) 9 agonist CpG 1018 adjuvant to enhance the immune response.
  • Price Action: DVAX shares are up 1.9% at $8.01 during the premarket session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareContractsSmall CapGeneralBriefsGermanyHepatits B
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!